Blair William & CO Novo Cure LTD Transaction History

Blair William & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$40.29 - $82.51 $36,502 - $74,754	906 Added 13.94%	7,406 $307,000
Q1 2023 May 12, 2023	SELL	$56.44 - $118.81 $16,932 - $35,643	-300 Reduced 4.41%	6,500 $390,000
Q3 2022 Nov 09, 2022	SELL	$67.99 - $89.57 $6,798 - $8,957	-100 Reduced 1.45%	6,800 $517,000
Q2 2022 Aug 10, 2022	SELL	$56.6 - $89.9 $169 - $269	-3 Reduced 0.04%	6,900 $480,000
Q1 2022 May 13, 2022	BUY	$60.15 - $84.52 $415,215 - $583,441	6,903 New	6,903 $572,000
Q3 2021 Nov 12, 2021	SELL	$116.17 - $194.55 $206,201 - $345,326	-1,775 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$124.11 - $190.17 $24,822 - $38,034	200 Added 12.7%	1,775 $235,000
Q4 2020 Feb 09, 2021	BUY	$112.16 - $174.14 $176,652 - $274,270	1,575 New	1,575 $273,000

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.79B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.